Nonetheless, recent studies from Segal and colleagues 12 have demonstrated increased systemic levels of the chemokines CXCL1 and CXCL5 as well as neutrophil elastase that correlated with lesion burden and clinical disability in MS patients arguing for a role for neutrophils in augmenting disease. This evidence concerns the gene ELANE and myeloid sarcoma.